Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.